@cosmauvic.bsky.social
Reposted
Reposted
Goldman Sachs analysts : The money men saying the quiet part out loud
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...
Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'
Goldman Sachs warns sales from the most successful disease treatments are difficult to maintain.
www.cnbc.com
December 18, 2024 at 10:48 AM
Goldman Sachs analysts : The money men saying the quiet part out loud
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...
Curing patients may not be a sufficiently profitable enterprise for biotech companies.
Chronic disease is a far more beneficial business model
www.cnbc.com/2018/04/11/g...